Progression-free survival was significantly longer in the olaparib plus chemotherapy group ( median @ months -LSB- @ % CI @-@ @ -RSB- ) than in the chemotherapy alone group ( median @ months -LSB- @ % CI @-@ @ ) ( HR @ -LSB- @ % CI @-@ @ -RSB- ; p = @ ) , especially in patients with BRCA mutations ( HR @ -LSB- @-@ @ -RSB- ; p = @ ) .